News | December 17, 2025
Glenmark secures exclusive multi-regional rights to Aumolertinib from Hansoh Pharma
Hansoh Pharma will receive an upfront payment in the low double-digit millions
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Ryght AI tackles these hurdles with its AI Site Twin platform
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
This launch is part of the company's strategy to expand its nutraceutical portfolio
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Subscribe To Our Newsletter & Stay Updated
